Takeda Pharmaceuticals U.S.A., Inc. refocusing efforts based on recent product launches in inflammatory bowel disease (IBD) and major depressive disorder (MDD), including the creation of business units to support efforts in these areas. Takeda will transfer the rights to develop and commercialize CONTRAVE (naltrexone HCl / bupropion HCl) in the U.S. back to Orexigen, allowing the company to focus resources in areas such as MDD, IBD, gout and diabetes. Following the launch of ENTYVIO (vedol...